Earliest functional declines in Huntington disease.
We examined the gold standard for Huntington disease (HD) functional assessment, the Unified Huntington's Disease Rating Scale (UHDRS), in a group of at-risk participants not yet diagnosed but who later phenoconverted to manifest HD. We also sought to determine which skill domains first weaken and the clinical correlates of declines. Using the UHDRS Total Functional Capacity (TFC) and Functional Assessment Scale (FAS), we examined participants from Huntington Study Group clinics who were not diagnosed at their baseline visit but were diagnosed at a later visit (N=265). Occupational decline was the most common with 65.1% (TFC) and 55.6% (FAS) reporting some loss of ability to engage in their typical work. Inability to manage finances independently (TFC 49.2%, FAS 35.1%) and drive safely (FAS 33.5%) were also found. Functional decline was significantly predicted by motor, cognitive, and depressive symptoms. The UHDRS captured early functional losses in individuals with HD prior to formal diagnosis, however, fruitful areas for expanded assessment of early functional changes are performance at work, ability to manage finances, and driving. These are also important areas for clinical monitoring and treatment planning as up to 65% experienced loss in at least one area prior to diagnosis.
Beglinger
Leigh J
LJ
Department of Psychiatry, The University of Iowa, Iowa City, IA, USA.
O'Rourke
Justin J F
JJ
Wang
Chiachi
C
Langbehn
Douglas R
DR
Duff
Kevin
K
Paulsen
Jane S
JS
D000328:Adult; D003072:Cognition Disorders / Q000209:etiology*; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000150:complications*; D008297:Male; D008875:Middle Aged; D019957:Motor Skills Disorders / Q000209:etiology*; D009069:Movement Disorders / Q000209:etiology*; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics; D012720:Severity of Illness Index
J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):310-4
11511702
Neurology. 2007 May 15;68(20):1710-7
17502553
FDA Consum. 2006 Nov-Dec;40(6):26-32
17333563
Mov Disord. 1996 Mar;11(2):136-42
8684382
J Am Geriatr Soc. 2008 Jan;56(1):37-44
18028344
Mov Disord. 2005 Mar;20(3):293-7
15584032
Neurology. 2001 Aug 28;57(4):658-62
11524475
J Nerv Ment Dis. 2004 Jan;192(1):72-4
14718780
Neurology. 2000 Jan 25;54(2):452-8
10668713
J Nerv Ment Dis. 1993 Mar;181(3):194-9
8445379
Neurology. 1979 Jan;29(1):1-3
154626
J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):120-2
12486282
Brain. 1998 Jul;121 ( Pt 7):1329-41
9679784
Cell. 1993 Mar 26;72(6):971-83
8458085
J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80
18096682